ArticleGene therapy2022

rAAV-based and intraprostatically delivered miR-34a therapeutics for efficient inhibition of prostate cancer progression.

Jianzhong Ai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.